The global primaquine market is expected to grow at a moderate CAGR during the forecast period (2021-2027). Primaquine is an antimalarial drug that is also used to treat pneumocystis pneumonia. It is used to treat malaria caused by Plasmodium vivax and Plasmodium ovale. It is used in conjunction with clindamycin to treat Pneumocystis pneumonia. It is administered orally. The FDA originally authorized primaquine in 1946. It is on the WHO's List of Essential Medications, which includes the safest and most effective medicines required in a health system. It can also be purchased as a generic drug.

Primaquine is primarily used to prevent Plasmodium vivax and Plasmodium ovale malaria recurrence. Patients with confirmed P. vivax or P. ovale infection who do not get primaquine face a high risk of recurrence for weeks or months (sometimes years). In regions nearing malaria eradication or confronting artemisinin resistance, the World Health Organization (WHO) recommends using the medication primaquine in combination with artemisinin-based combination treatment (ACT) to prevent Plasmodium falciparum transmission. The rise in malaria incidence in developing nations is a significant factor driving the growth of the primaquine. Furthermore, increased government awareness campaigns and increased research for novel antimalarial medicines are some of the causes driving the market growth.  

Primaquine is used to treat pneumocystis pneumonia (PCP), a fungal infection that affects patients with AIDS and, less often, those on immunosuppressive medications. PCP is frequently coupled with clindamycin to treat it successfully. According to National Center for Biotechnology Information (NCBI), the prevalence of PCP without chemoprophylaxis, in transplant patients range from 5% to 25%, in patients with collagen vascular disease from 2% to 6%, and in cancer patients from 1% to 25%. CD4+ lymphocyte defects are a major risk factor for PCP, although the immunological response to Pneumocystis is complicated. Thus, the rising prevalence of PCP is expected to drive the adoption of primaquine during the forecast period.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product Type – Injectables, Capsules, and Tablets 

o By Application – Malaria and Pneumocystis Pneumonia 

o By Distribution Channel – Hospitals and Clinics, Online Drug Stores, and Others 

• Competitive Landscape- Cyper Pharma, Pfizer Inc., and Others

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Primaquine Market Report Segmentation

By Product Type

• Injectables
• Capsules
• Tablets

By Application

• Malaria
• Pneumocystis Pneumonia

By Distribution Channel

• Hospitals and Clinics
• Online Drug Stores
• Others

By Region